Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

    Results: 1 to 20 of 45

    1.

    Management of advanced genitourinary tumors.

    Pietrantonio F, Biondani P, Verzoni E, Procopio G.

    Tumori. 2012 Mar-Apr;98(2):264-6. doi: 10.1700/1088.11940.

    PMID:
    22677995
    [PubMed - indexed for MEDLINE]
    2.

    The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

    Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T.

    Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1391-9. doi: 10.1007/s00259-012-2149-1. Epub 2012 May 30.

    PMID:
    22644713
    [PubMed - indexed for MEDLINE]
    3.

    Successful enucleation of a fluorine-18-fluorodeoxyglucose positron emission tomography positive esophageal leiomyoma in the prone position using sponge spacer and intra-esophageal balloon compression.

    Shimada Y, Okumura T, Nagata T, Sawada S, Yoshida T, Yoshioka I, Moriyama M, Tsukada K.

    Gen Thorac Cardiovasc Surg. 2012 Aug;60(8):542-5. doi: 10.1007/s11748-012-0027-1. Epub 2012 May 8.

    PMID:
    22566256
    [PubMed - indexed for MEDLINE]
    4.

    Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

    McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ.

    J Clin Oncol. 2012 May 10;30(14):1628-34. doi: 10.1200/JCO.2011.39.1938. Epub 2012 Mar 26.

    PMID:
    22454415
    [PubMed - indexed for MEDLINE]
    5.

    A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

    Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK.

    Nature. 2012 Mar 18;483(7391):613-7. doi: 10.1038/nature10937.

    PMID:
    22425996
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.

    Rousseau C, Ferrer L, Supiot S, Bardiès M, Davodeau F, Faivre-Chauvet A, Baumgartner P, Wijdenes J, Lacombe M, Barbet J, Guillaume T, Moreau P, Harousseau JL, Kraeber-Bodéré F, Cherel M.

    Tumour Biol. 2012 Jun;33(3):679-88. doi: 10.1007/s13277-012-0362-y. Epub 2012 Mar 3.

    PMID:
    22389160
    [PubMed - indexed for MEDLINE]
    7.

    ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.

    Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA.

    J Nucl Med. 2012 Apr;53(4):567-74. doi: 10.2967/jnumed.111.094425. Epub 2012 Mar 1.

    PMID:
    22381410
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.

    Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, Colevas AD, Iagaru AH, Graves EE, Loo BW Jr, Le QT.

    Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1514-20. doi: 10.1016/j.ijrobp.2011.10.023. Epub 2012 Jan 21.

    PMID:
    22270174
    [PubMed - indexed for MEDLINE]
    9.

    Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma.

    Chang KP, Tsang NM, Liao CT, Hsu CL, Chung MJ, Lo CW, Chan SC, Ng SH, Wang HM, Yen TC.

    J Nucl Med. 2012 Jan;53(1):21-8. doi: 10.2967/jnumed.111.090696. Erratum in: J Nucl Med. 2012 Feb;53(2):342.

    PMID:
    22213820
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.

    Mortazavi-Jehanno N, Giraudet AL, Champion L, Lerebours F, Le Stanc E, Edeline V, Madar O, Bellet D, Pecking AP, Alberini JL.

    Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):450-60. doi: 10.1007/s00259-011-1981-z. Epub 2011 Dec 20.

    PMID:
    22183107
    [PubMed - indexed for MEDLINE]
    11.

    Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non--small-cell lung cancer.

    Skoura E, Datseris IE, Platis I, Oikonomopoulos G, Syrigos KN.

    Clin Lung Cancer. 2012 May;13(3):181-7. doi: 10.1016/j.cllc.2011.05.004. Epub 2011 Dec 1. Review.

    PMID:
    22137017
    [PubMed - indexed for MEDLINE]
    12.

    A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.

    O'Brien ME, Myerson JS, Coward JI, Puglisi M, Trani L, Wotherspoon A, Sharma B, Cook G, Ashley S, Gunapala R, Chua S, Popat S.

    Eur J Cancer. 2012 Jan;48(1):68-74. doi: 10.1016/j.ejca.2011.10.033. Epub 2011 Nov 24.

    PMID:
    22119198
    [PubMed - indexed for MEDLINE]
    13.

    Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.

    Cornec D, Tempescul A, Querellou S, Hutin P, Pers JO, Jamin C, Bendaoud B, Berthou C, Renaudineau Y, Youinou P.

    Ann Hematol. 2012 May;91(5):715-21. doi: 10.1007/s00277-011-1369-y. Epub 2011 Nov 16.

    PMID:
    22083514
    [PubMed - indexed for MEDLINE]
    14.

    A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma.

    Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, Scheuerer C, Peschel C, Schwaiger M, Dechow T, Keller U.

    J Nucl Med. 2011 Dec;52(12):1898-902. doi: 10.2967/jnumed.111.094698. Epub 2011 Nov 7.

    PMID:
    22065875
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer.

    Han MW, Lee HJ, Cho KJ, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY.

    Head Neck. 2012 Oct;34(10):1395-402. doi: 10.1002/hed.21945. Epub 2011 Nov 3.

    PMID:
    22052623
    [PubMed - indexed for MEDLINE]
    16.

    3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.

    Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC.

    Cancer. 2012 Jun 15;118(12):3135-44. doi: 10.1002/cncr.26630. Epub 2011 Oct 21.

    PMID:
    22020872
    [PubMed - indexed for MEDLINE]
    17.

    Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography.

    Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR.

    Hum Gene Ther. 2012 Jan;23(1):91-7. doi: 10.1089/hum.2011.141. Epub 2011 Oct 14.

    PMID:
    21895536
    [PubMed - indexed for MEDLINE]
    18.

    Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma.

    Nakazawa A, Higuchi T, Oriuchi N, Arisaka Y, Endo K.

    Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1869-75. doi: 10.1007/s00259-011-1872-3. Epub 2011 Jul 6.

    PMID:
    21732103
    [PubMed - indexed for MEDLINE]
    19.

    Are we undertreating invasive bladder cancer? Optimizing outcomes in a high-risk disease.

    Blais N.

    Curr Opin Support Palliat Care. 2011 Sep;5(3):192-8. doi: 10.1097/SPC.0b013e3283490441. Review.

    PMID:
    21725243
    [PubMed - indexed for MEDLINE]
    20.

    The role of positron emission tomography in management of small cell lung cancer.

    Thomson D, Hulse P, Lorigan P, Faivre-Finn C.

    Lung Cancer. 2011 Aug;73(2):121-6. doi: 10.1016/j.lungcan.2011.03.013. Epub 2011 Apr 27. Review.

    PMID:
    21524814
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Search details

      See more...

      Recent activity

      • "Positron-Emission Tomography"[Mesh] AND ("fluorodeoxyglucose f18... (45)
        "Positron-Emission Tomography"[Mesh] AND ("fluorodeoxyglucose f18"[MeSH Terms] OR FDG[All Fields] OR F18[All Fields] OR Fluorodeoxyglucose[All Fields]) AND "Biological Markers"[Mesh] AND "Neoplasms"[Mesh] AND "Treatment Outcome"[MeSH] AND ("2007/06/30"[PDAT] : "2012/06/27"[PDAT] AND English[lang]) AND ("2007/01/01"[PDAT] : "2050/12/31"[PDAT])
        Search
        PubMed

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk